Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Disease area: Thoracic oncology

Abstract

INTRODUCTION: Many have reported that glycosaminoglycans (GAGs) have different behaviors in the presence of malignant tissues.In this study, we examined different GAGs concentrations and their impact on diagnosis and/or prognosis of patients with non small cell lung cancer.
METHODS: Sulfated GAGs and Hyaluronic Acid(HA) were examined in tumoral and non-tumoral tissues from 45 lung cancer patients.Tissue samples were dehydrated and incubated with a proteolytic enzyme.The levels of HA were measured by a noncompetitive ELISA-like fluorometric assay. The sulfated GAG chains (heparan, dermatan and chondroitin sulfate - HS, DS and CS), were precipitated, dissolved in DNAse and their concentrations were identified after gel electrophoresis.
RESULTS: HS and HA showed significantly higher concentration in tumoral than in normal areas (p=0.02 and p=0.0001, respectively; Fig1A/B).The Kaplan-Meier survival curves shows that tissues with lower concentrations of HA have better long-term survival than those with higher concentrations (Log Rank=3,59; p=0.05;Fig1C).One hundred% of tumoral areas presented CS while the normal almost never (p=0.0001;Fig1D).

CONCLUSIONS: The results presented suggest a possible role of these molecules on lung cancer development, but more importantly provide potential biochemical markers for differentiating normal from lung cancer patients.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Peres Rangel, V. Karen de Sá, J. R. Maciel Martins, E. R. Parra, A. Mendes, D. Carrasco, E. Olivieri, V. L. Capelozzi (São Paulo, Brazil). Amorfous components of the extracellular matrix have impact as new biochemical markers on malignancy characterization and prognosis of non-small cell lung cancer. Eur Respir J 2011; 38: Suppl. 55, 4503

Member's Comments

No comment yet.

Related content which might interest you: Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002 Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Hypoxia-response gene signatures as predictive and prognostic biomarkers in advanced non-squamous non-small cell lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Clinical implication of stem cell markers in N2 positive non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Correlation between the activation of coagulation-fibrinolysis system and prognosis of nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001 Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 482s Year: 2005 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015